GlassScriptPhysician profile
Sanjay Ahlawat
NPI 1245485895
$1,120.77
in general payments reported to CMS, 2019-2025
21 companies · $948 in 2025
The $948 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.99 · 2023: $46.00 · 2024: $111 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $404.37 | 2025 | |
| Exact Sciences Corporation | $92.27 | 2024-2025 | Cologuard Collection Kit |
| Braeburn INC. | $82.61 | 2025 | Brixadi |
| Lundbeck LLC | $73.09 | 2025 | Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $47.99 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $43.96 | 2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $37.29 | 2025 | Austedo Xr |
| Alkermes, INC. | $34.97 | 2025 | Aristada, Vivitrol, Aristada Initio |
| Indivior INC. | $34.20 | 2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $33.96 | 2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $33.39 | 2025 | Rexulti |
| Novo Nordisk INC | $31.64 | 2024 | Wegovy |
| Vanda Pharmaceuticals INC. | $31.10 | 2025 | Fanapt, Hetlioz |
| Glaxosmithkline, LLC. | $29.49 | 2023 | Trelegy Ellipta |
| Neurocrine Biosciences, INC. | $18.82 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $16.63 | 2025 | Fibroscan |
| Astrazeneca Pharmaceuticals LP | $16.51 | 2023 | Breztri |
| E.R. Squibb & Sons, L.L.C. | $15.40 | 2025 | Cobenfy |
| Daiichi Sankyo INC. | $14.99 | 2022 | |
| Luye Pharma (USA) LTD. | $14.36 | 2025 | Erzofri Extended-Release |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.73 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Ahlawat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.